Latest DecisionDx-UM Stories
RadioMedix, Inc., a Houston-based biotechnology company and Viewpoint Molecular Targeting LLC of Iowa City were awarded a grant by the Small Business Innovation Research (SBIR) program from the
Statement from Tim Turnham, Executive Director, Melanoma Research Foundation WASHINGTON, Sept.
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival.
DecisionDx-Melanoma identifies patients with negative sentinel lymph node biopsies who are at high risk of metastasis FRIENDSWOOD, Texas, May 14, 2014 /PRNewswire/ -- Castle Biosciences Inc.
Presentation at the American Association for Thoracic Surgery 94th Annual Meeting TORONTO, April 29, 2014 /PRNewswire/ -- Castle Biosciences Inc.
Data presented at the Latest in Dermatology Research Symposia session of 72nd Annual Meeting of the American Academy of Dermatology DENVER, March 22, 2014 /PRNewswire/ -- Castle Biosciences
DURHAM, N.C. and ALISO VIEJO, Calif., Jan. 28, 2014 /PRNewswire/ -- bioMerieux, Inc.
- A political dynamiter.